“…Intrathecal Gd injection is not approved by the FDA, though its safety has been reported in several pilot studies in Europe. [2][3][4]6,[9][10][11][12][13][14] Tolerance and dose limits of intrathecal Gd injection were established in animal model studies, and different Gd compounds (eg, gadodiamide, gadobenate dimeglumine, and Gd-DTPA) were compared in different experimental animal protocols. 5,[14][15][16][17] High-dose intraventricular Gd injection was reported to result in behavioral and neurologic disturbances (focal seizures, ataxia, latent tremor) with histopathologic changes (loss of oligodendroglia, astrocytic hypertrophy, and eosinophilia); on the other hand, it was concluded that these changes and distur-bance did not occur if the total injected dose wasϽ15 mL (3.3 mmol/g).…”